

ALEXION PHARMACEUTICAL INC

ISIN: US0153511094 WKN: 015351109 Asset Class: Stock

Company



2019/11/13 22:00:00

Price

107.13

USD

Difference

▲ -2.11%(-2.31)



Contact Details

ALEXION PHARMACEUTICALS
INC.

Susan Altschuller

Seaport Boulevard 121

02210 Boston Massachusetts

Tel: +1-475-230-2596

Fax: +1-203-271-8198

Web:

<http://www.alxn.com/>

E-mail: IR@Alexion.com

Company Profile

Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare disorders. Alexion developed and commercializes Soliris® (eculizumab), the first and only approved complement inhibitor to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two life-threatening ultra-rare disorders. As the global leader in complement inhibition, Alexion is strengthening and broadening its portfolio of complement inhibitors, including evaluating potential indications for eculizumab in additional severe and ultra-rare disorders. Alexion's metabolic franchise includes two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare disorders, Strensiq® (asfotase alfa) to treat patients with hypophosphatasia (HPP) and Kanuma® (sebelipase alfa) to treat patients with lysosomal acid lipase deficiency (LAL-D). In addition, Alexion is advancing the most robust rare disease pipeline in the biotech industry with highly innovative product candidates in multiple therapeutic areas.

Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2018		2017		2016	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	3,385,000,000		2,953,900,000		2,578,000,000	
Common stock capital		23,000		23,000		23,000
Fixed assets	-		-		-	
Equity capital of a company		9,165,300,000		8,893,100,000		8,694,000,000
Cash and cash equivalents	1,365,500,000		584,400,000		966,000,000	
Accrued liabilities		-		-		-
Other assets	-		-		-	
Current liabilities		1,174,000,000		952,500,000		823,000,000
Prepayments and accrued income		-		-		-
Non-current liabilities		-		-		-
Different income		-		15,900,000		37,000,000
Other liabilities		-		-		-
Total assets	13,931,900,000	13,931,900,000	13,583,300,000	13,583,300,000	13,253,000,000	13,253,000,000

Balance notes

	2018	2017	2016
Accounting standard	US-GAAP	US-GAAP	US-GAAP
Employees	2,656	2,525	3,121
Equity ratio	65.79%	65.47%	65.60%
Debt-equity ratio	52.01%	52.74%	52.44%

Others

	2018	2017	2016
Tax Expense Rate	67.96%	19.08%	30.73%

ALEXION PHARMACEUTICAL INC

ISIN: US0153511094 WKN: 015351109 Asset Class: Stock

Income statement

	2018	2017	2016
Turnover	4,131,200,000	3,551,100,000	3,084,000,000
Net income	77,600,000	443,300,000	399,000,000
EBIT	249,350,640	568,947,280	600,036,800
Operating income before taxes	242,200,000	547,800,000	576,000,000
Cash Flow	426,000,000	1,115,600,000	1,086,000,000
Net interest income	-32,900,000	-79,900,000	-86,000,000
Research and development expenses	730,400,000	878,400,000	757,000,000
Income taxes	164,600,000	104,500,000	177,000,000
Result from investments in subsidiaries, associates and other	-	-	-
Revenues per employee	1,409,834	1,274,739	895,654

Board of Directors

Members of Management Board

David R. Brennan	Chairman of Board of Directors
Paul A. Friedman	Member of Board of Directors
Ludwig N. Hantson	Member of Board of Directors
Judith Reinsdorf	Member of Board of Directors
John T. Mollen	Member of Board of Directors
Francois Nader	Member of Board of Directors
Deborah Dunsire	Member of Board of Directors
Christopher J. Coughlin	Member of Board of Directors
Felix J. Baker	Member of Board of Directors
Andreas Rummelt	Member of Board of Directors
Ludwig N. Hantson	Chairman of Managing Board
Rana Strellis	Member of Executive Committee
Paul J. Clancy	Member of Executive Committee
John Orloff	Member of Executive Committee
Indrani Franchini	Member of Executive Committee
Ellen Chiniara	Member of Executive Committee
Brian Goff	Member of Executive Committee
Aradhana Sarin	Member of Executive Committee
Anne-Marie Law	Member of Executive Committee